HUMAN ENDOGENOUS RETROVIRUS TYPE W ANTIGENAEMIA (MSRV-ENVELOPE) IN PATIENTS WITH CIDP.

Authors:
(1) Alain Créange, (2) Thierry Kuntzer, (2) Raphael Faucard (3), (2) Petrica-Adrian Panaite, (1) Catherine Lesage (3) Burgelin Ingrid, (3) Bernard Corinne, (3) Curtin François, (2) Andreas J. Steck, (3) Hervé Perron

Institutions:
(1) Université Paris 12 and Groupe Hospitalier Henri Mondor, Créteil, France
(2) Lausanne University Hospital (CHUV), Lausanne, Switzerland;
(3) Geneuro SA, Plan-Les-Ouates, Switzerland

Body of abstract:
The human genome comprises nearly 45% of mobile genetic elements, in which human endogenous retroviruses (HERV) represent 8% of total DNA. HERV-W family retains copies expressing an envelope protein (MSRV-Env), which activates a pro-inflammatory and autoimmune cascade through interaction with Toll-Like receptor 4 (TLR4) on antigen-presenting cells. HERV-W has now consistently been associated with Multiple Sclerosis (MS) and HERV-W was shown to be activated by infectious agents suspected to play a role in the ethiopathogeny of MS. Nonetheless, in a pilot study addressing various neurological diseases, a cluster of patients with CIDP also revealed to have positive antigenaemia for MSRV-Env. Since CIDP shares common and analogous features with MS pathogenesis, we have initiated a study exploring whether this immunopathogenic HERV-W protein could be also be involved in certain cases of CIDP.

For the purpose, we have performed ELISA quantification of HERV-W/MSRV-Env antigen from CIDP patients, neurological and healthy controls with a dedicated assay. The results obtained with present numbers of patients included in the study revealed 15/30 (50%) positives in CIDP from Créteil (France) and 9/19 (47%) from Lausanne (Switzerland),
but only 3/18 (17\%) in apparently healthy controls (HC). A statistical difference with controls is reached with Chi-square test for separate CIDP series (p<0.05) or with CIDP cases altogether (24/49, p<0.01). Inclusion of controls with other neurological diseases has revealed few positive (4/20; p<0.02 compared with all CIDP), comprising one case with spastic paraparesis, two with metabolic neuropathies and one with Parkinson's disease.

The present results confirm the existence of a group (about one-half) of CIDP patients with positive antigenaemia for HERV-W neuroinflammatory envelope protein. The potential involvement of this HERV protein in the pathophysiology of certain cases of CIDP is now raised. Such an involvement of HERV-W in CIDP may open novel and targeted therapeutic perspectives.